Kira Pharmaceuticals is a global biotechnology company dedicated to pioneering transformative therapies for patients with complement-mediated diseases. Utilizing its proprietary LOGIC platform, the company has developed a diverse pipeline of nine novel complement assets targeting various points in the complement cascade. With a mission to advance treatments for these severe conditions, Kira Pharmaceuticals leverages the expertise of complement biology specialists, drug developers, and protein engineers.
The company has made significant strides in the biotech industry, driven by its innovative approach and experienced team. Kira Pharmaceuticals' robust pipeline and strategic focus on validated targets have positioned it as a leader in the field of complement disease therapies. The company's impact is underscored by its commitment to addressing unmet medical needs and improving patient outcomes globally.
